Laser Photocoagulation for Neovascular Lesions Nasal to the FoveaResults From Clinical Trials for Lesions Secondary to Ocular Histoplasmosis or Idiopathic Causes
Macular Photocoagulation Study Group
Arch Ophthalmol. 1995;113(1):56-61.
Abstract
| |
Objective
To determine whether laser photocoagulation of peripapillary choroidal neovascularization (CNV) or large neovascular lesions that are located nasal to the fovea is beneficial with respect to preservation of remaining vision—consistent with the overall study findings.
Patients and Interventions
A total of 113 eyes (112 patients) having either peripapillary CNV or CNV that was located nasal to the fovea and larger than 750 µm in longest diameter associated with either ocular histoplasmosis or idiopathic causes were identified from the eyes that were randomly assigned to either laser photocoagulation or observation only in clinical trials conducted by the Macular Photocoagulation Study Group.
Main Outcome Measures
Visual acuity and change in visual acuity from baseline examination were compared for laser-treated and untreated eyes.
Results
At the 3-year examination, 11% (6/54) of the treated eyes vs 41% (21/51) of the untreated eyes had lost six or more lines of visual acuity (P<.001). Among eyes with peripapillary lesions, 14% (3/22) of the treated eyes vs 26% (6/23) of the untreated eyes had lost six or more lines of visual acuity at the 3-year examination (P=.29). Among eyes with nasal lesions, 9% (3/32) of the treated eyes vs 54% (15/28) of the untreated eyes had lost six or more lines of visual acuity at the 3-year examination (P<.001).
Conclusion
Results from the subset of patients who had extrafoveal or juxtafoveal peripapillary CNV or CNV that was located nasal to the fovea were consistent with the beneficial results of treatment observed in the entire group of eyes that were studied by the Macular Photocoagulation Study Group.
Author Affiliations
Prepared for the Macular Photocoagulation Study Group by Marta J. Marsh, MS; Stuart L. Fine, MD; Judith Alexander; Andrew P. Schachat, MD; Maureen G. Maguire, PhD; Neil M. Bressler, MD; Noreen B. Javornik, MS; Michael L. Klein, MD; Lawrence J. Singerman, MD; and Barbara S. Hawkins, PhD. A complete list of the members of the Macular Photocoagulation Study Group as of March 30, 1993, was published in the April 1994 issue of the Archives (1994;112:482). No member of the Macular Photocoagulation Study Group has any proprietary interest in the development or marketing of any commercially available products used by this or any other Macular Photocoagulation Study clinical trial.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab
Figueroa et al.
Br J Ophthalmol 2008;92:1244-1247.
ABSTRACT
| FULL TEXT
Treatment of peripapillary choroidal neovascularisation
Postelmans et al.
Br J Ophthalmol 2008;92:721-722.
FULL TEXT
Surgical treatment of peripapillary choroidal neovascularisation
Binder
Br J Ophthalmol 2007;91:990-991.
FULL TEXT
Surgical treatment of peripapillary choroidal neovascularisation
Aisenbrey et al.
Br J Ophthalmol 2007;91:1027-1030.
ABSTRACT
| FULL TEXT
Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation
Giovannini et al.
Br J Ophthalmol 2007;91:620-623.
ABSTRACT
| FULL TEXT
Surgical Removal vs Observation for Subfoveal Choroidal Neovascularization, Either Associated With the Ocular Histoplasmosis Syndrome or Idiopathic: I. Ophthalmic Findings From a Randomized Clinical Trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9
Submacular Surgery Trials Research Group
Arch Ophthalmol 2004;122:1597-1611.
ABSTRACT
| FULL TEXT
|
